

Q1-2023 Pharma Services Update

Market Update

Despite an uncertain macroeconomic environment, recessionary fears, the war in Ukraine, and the impact of rising interest rates, M&A activity in pharma services displayed strong resiliency Q1-23, mostly led by add-on acquisitions to existing platforms. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including reducing costs, technological advancements, access to value-added specialty services. Certain therapeutic areas, oncology and CNS diseases for example, will likely remain popular due to a robust pipeline of R&D activity.

Provident expects M&A activity to rebound in the second half of 2023 as companies look to fill the potential growth gap from the \$100B in patents set to expire by 2030.

Notable Transaction



Clinical Trials of America is a multi-therapeutic clinical trials company that brings to IMA four new independent and six embedded site locations in Louisiana and North Carolina

With CTA's deep therapeutic expertise in cardiology, gastroenterology, dermatology, vaccines, family medicine and psychiatry, the transaction adds scale, enhances diversity and further extends

the reach of IMA Clinical Research in the Southeast.

IMA Clinical Research has grown 300% over the past three years; the transaction increases division's network to 17 sites and expands access to patients in additional therapeutic areas.

Select Transactions:

Month	Acquirer	Target	Commentary
March	Fingerpaint GROUP KNOX-LANE	PHARMA HEALTH Labs	PharmaHEALTHLabs is an agency with scientific healthcare communications expertise within oncology and biologics. Fingerpaint Group, an integrated collective of healthcare companies that offer commercialization solutions spanning the full product life cycle, is growing its robust medical communications expertise with the acquisition of PharmaHEALTHLabs
February	THOMPSON STREET CAPITAL PARTNERS	Sabai Global	Thompson Street Capital Partners, a private equity firm based in St. Louis, announced a growth investment in Sabai Global, a Chesterfield, MO based provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs, academic health systems, and clinical research site networks.
February	CLAIRVEST	Boca Biolistics	Boca Biolistics is a leading clinical research organization and biomaterials company focused on the procurement, storage, and sale of human biological samples (specializing in infectious diseases and oncology) used for clinical trials and diagnostic development.
January	SYNER-G BioPharma Group Riverside PARTNERS	RMC PHARMA RESPONSIVE • MEASURED • CREATIVE	RMC was founded to provide comprehensive services to companies developing and commercializing health care products and has now served more than 350 different clients across North America, Europe, Australia, South America and Asia. The acquisition of RMC provides additional depth to Syner-G's suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy

Provident Pharma Services Industry Coverage Team

Michael Patton
Managing Director
mpatton@providenthp.com
(617) 226-4272

Kevin McDermott
Senior Associate
kmcdermott@providenthp.com
(310) 359-6627

Daniel O'Brien
Associate
dobrien@providenthp.com
(617) 226-4292